2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Monday, September 23, 2019

1:45pm-3:15pm: Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data

C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San Francisco, CA, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Safety of Iron Chelation in Patients with Brain Iron Overload

C. Fradette, T. Klopstock, L. Neumayr, I. Karin, G. Zorzi, T. Kmieć, B. Büchner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, F. Zibordi, N. Nardocci, A. Stilman, M. Spino, E. Vichinsky, F. Tricta (Toronto, ON, Canada)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

Neuropharmacology · Les Muses Terrace, Level 3

1:45pm-3:15pm: Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)

A. Gómez López, I. Pareés Moreno, S. Fanjul Arbós, JL. López Sendon, JC. Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: Safinamide reduces membrane excitability and synaptic transmission of striatal spiny projection neurons in a rat model of Parkinson’s disease

A. Tozzi, M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

Neuropharmacology · Les Muses Terrace, Level 3

1:45pm-3:15pm: Safinamide: real world evidence in Toledo´s Movement Disorders Unit

N. López-Ariztegui, MI. Morales-Casado, JC. Segundo-Rodríguez, A. Avila-Fernández, N. García-Alvarado, J. Pérez-Matos (Toledo, Spain)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3